On behalf of DCR facilitate the conduct of an observational study to characterize patients with covid-19 infection (10,000 subjects).
Active Awarded Last action
- Contract number
- 75N91020F00008
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,109,529
Award facts
- Contract value 100% obligated
- $18,109,529.00 Current and potential, with all options
- Completion date 96% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $630,827 | |
| Definitize Letter Contract | $4,983,362 | |
| Supplemental Agreement for work within scope | $7,568,588 | |
| Original award | $4,926,752 |
About this award
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to facilitate the conduct of an observational study to characterize patients with COVID-19 infection (10,000 subjects). The contract has a ceiling value of $18,109,529.00 with a period of performance through January 31, 2027. It is a cost-plus-fixed-fee delivery order contract with no set-aside designation. The prime contractor, Leidos Biomedical Research Inc., serves as a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI) and has supported various research efforts across different disease areas, including COVID-19. Leidos Biomedical Research has subcontracted with Proteinsimple, a subsidiary of Bio-Techne Corporation, for the purchase of capital equipment such as the JESS System to support the research activities under this contract.
Quick answers
Who was awarded contract 75N91020F00008?
75N91020F00008 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on April 3, 2020.
How much is contract 75N91020F00008 worth?
The government has obligated $18,109,529 on 75N91020F00008.
Which agency awarded contract 75N91020F00008?
National Cancer Institute (National Institutes of Health) awarded 75N91020F00008, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91020F00008 an order under another contract?
Yes. 75N91020F00008 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00008 competed?
The extent of competition for 75N91020F00008 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award